NDA 203139 Clinical Pharmacology Review – Sildenafil ...
Table of contents 1 Executive Summary .........................................................................................................................4
1.1 Recommendations ...............................................................................................................4
2 Executive Summary .........................................................................................................................5
3 Question Based Review ...................................................................................................................8
3.1 General Attributes of the drug.............................................................................................8
3.2 General Clinical Pharmacology ..........................................................................................8
3.3 Intrinsic Factors.................................................................................................................25
3.4 Extrinsic Factors................................................................................................................26
3.5 General Biopharmaceutics ................................................................................................27
3.6 Analytical Section .............................................................................................................28
4 DRAFT Labeling Recommendations.............................................................................................29
Appendix (CLINICAL PHARMACOLOGY ? Individual Study Review) ...........................................30
List of Tables Table 1. The dosing recommendation in the proposed labeling................................................................... 7
Table 2. Pulmonary Hemodynamics (PVRI) Treatment Comparison to Placebo (n=52) ......................... 13
Table 3. Dose-response for safety of sildenafil in pediatrics during randomized portion of A1481131 .. 16
Table 4. Dose-response for mortality in pediatrics during the long-term extension Study A1481156 ..... 17
Table 5. Dose-response for mortality in pediatrics during the long-term extension Study A1481156 ..... 17
Table 6. Dose titrations by dosing group in long term extension trial ...................................................... 20
Table 7. Shift table for Randomized and Modal Dose Groups, N (deaths)............................................... 20
Table 8. Comparison of Exercise Capacity and Pulmonary Vascular Resistance Index Effect in pediatric
(medium and high doses pooled) and adult (20 mg TID) populations .............................................. 22
Table 9. Sildenafil doses (mg) given TID for the Pivotal trial in Pediatrics (Study A1481131) .............. 23
Table 10. Summary of sildenafil clearance (CL/F) in children 1-20 to ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- role of viagra after radical prostatectomy
- patient information sildenafil tablets sil den a fil 20
- sildenafil revatio
- signs of illness what you need to know before you take
- apo sildenafil pht 20 mg tablets contains the active
- 20 mg 40 mg riyadh pharma
- package leaflet information for the patient sildenafil
- reference id 3471998
- nda 203139 clinical pharmacology review sildenafil
Related searches
- fda nda submission process
- nda pdf financial information
- journal clinical pharmacology impact factor
- free pharmacology review for nurses
- clinical pharmacology journal
- clinical pharmacology journals
- nursing pharmacology review pdf
- journal of clinical pharmacology impact
- nda application form 2019
- free nda pdf
- sildenafil vs sildenafil citrate difference
- ups nda tracking